Beaufort Securities Reaffirms “Speculative Buy” Rating for ValiRx Plc (VAL)
ValiRx Plc (LON:VAL)‘s stock had its “speculative buy” rating reiterated by equities researchers at Beaufort Securities in a research report issued on Friday. They presently have a GBX 6.50 ($0.08) price target on the stock. Beaufort Securities’ price target would suggest a potential upside of 195.45% from the company’s previous close.
Shares of ValiRx Plc (LON VAL) traded up 3.53% on Friday, hitting GBX 2.20. The company’s stock had a trading volume of 224,875 shares. ValiRx Plc has a one year low of GBX 2.00 and a one year high of GBX 11.49. The stock has a 50-day moving average price of GBX 2.24 and a 200 day moving average price of GBX 3.74. The firm’s market cap is GBX 2.88 million.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/17/beaufort-securities-reaffirms-speculative-buy-rating-for-valirx-plc-val.html.
About ValiRx Plc
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with MarketBeat.com's FREE daily email newsletter.